ArriVent Biopharma price target raised to $30 from $25 at H.C. Wainwright
PremiumThe FlyArriVent Biopharma price target raised to $30 from $25 at H.C. Wainwright
3M ago
ArriVent Biopharma reports Q2 EPS (65c), consensus (64c)
Premium
The Fly
ArriVent Biopharma reports Q2 EPS (65c), consensus (64c)
3M ago
ArriVent Biopharma initiated with an Outperform at Oppenheimer
Premium
The Fly
ArriVent Biopharma initiated with an Outperform at Oppenheimer
4M ago
ArriVent Biopharma initiated with a Buy at H.C. Wainwright
PremiumThe FlyArriVent Biopharma initiated with a Buy at H.C. Wainwright
6M ago
Premium
Company Announcements
ArriVent BioPharma Welcomes Kristine Peterson to Board
7M ago
Drugmakers look to alternative suppliers after draft U.S. legislation, FT says
Premium
The Fly
Drugmakers look to alternative suppliers after draft U.S. legislation, FT says
7M ago
Opening Day: Chromocell Therapeutics, Unusual Machines make public debut
PremiumThe FlyOpening Day: Chromocell Therapeutics, Unusual Machines make public debut
9M ago
Premium
Company Announcements
ArriVent BioPharma IPO Raises $175 Million Successfully
9M ago
Premium
Company Announcements
ArriVent BioPharma Adopts New Bylaws Post-IPO
9M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100